Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2017
Price :
$35
*
At a glance
- Drugs Dapivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 09 Feb 2017 New trial record